


VP-14637

Cat. No.:	HY-12994
CAS No.:	235106-62-4
Molecular Formula:	C ₂₅ H ₂₂ N ₁₀ O ₃
Molecular Weight:	510.51
Target:	RSV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	MDT-637 (VP 14637) is a novel respiratory syncytial virus (RSV) fusion inhibitor with an IC ₅₀ of 1.42 ng/mL.
IC ₅₀ & Target	IC ₅₀ : 1.42 ng/mL (RSV) ^[1]
In Vitro	MDT-637 has broad in vitro antiviral activity on clinical strains of different RSV genotypes and clades. MDT-637 inhibits three laboratory strains (RSV-A Long, RSV-A2, and RSV-9320) and four clinical strains (RSV-Memphis-37, RSV-LAP0824, and RSV-HAN1135) with IC ₅₀ s range from 0.36 to 3.4 ng/mL ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]	The laboratory and clinical isolates of RSV and various concentrations (ranging from 0.1 μM to 31.6 pM) of MDT-637 (or ribavirin) are added to the HEP-2 cell monolayers at the same time. After 72 hours of incubation at 37°C, the cells and supernatants are harvested. An aliquot is immediately serially diluted and used for plaque assay ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
---------------------------	---

REFERENCES

[1]. Kim YI, et al. The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin. *Influenza Other Respir Viruses*. 2017 Nov;11(6):525-530.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA